Chemistry:Atumelnant

From HandWiki

Atumelnant (INN; developmental code name CRN04894) is an investigational new drug developed by Crinetics Pharmaceuticals for the treatment of adrenocorticotropic hormone (ACTH)-dependent endocrine disorders.[1] It is a selective antagonist of the melanocortin type 2 receptor (MC2R), also known as the ACTH receptor, which is primarily expressed in the adrenal glands.[1][2] The drug is orally active.[1] Atumelnant is being evaluated to treat conditions such as congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome caused for example by pituitary adenomas.[3]

References

  1. ↑ 1.0 1.1 1.2 "Crinetics Pharmaceuticals". 21 January 2025. https://adisinsight.springer.com/drugs/800055522. 
  2. ↑ "Atumelnant (CRN04894)". crinetics.com. 14 August 2020. https://crinetics.com/pipeline/atumelnant-cushings-syndrome-cah/. 
  3. ↑ "Pharmacological management of pituitary adenomas - what is new on the horizon?". Expert Opinion on Pharmacotherapy 26 (2): 119–125. December 2024. doi:10.1080/14656566.2024.2446625. PMID 39718553. 





Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Atumelnant&oldid=4030877"